ESPU Congress 2018 - Abstract Book

157 11–14 APRIL, 2018, HELSINKI, FINLAND 08:13–08:16 S21-2 (PP) EFFICACY AND SAFETY OF TRANSDERMAL OXYBUTYNIN VERSUS ORAL OXYBUTYNIN IN MANAGEMENT OF PAEDIATRIC NEUROPATHIC BLADDER Emily RICE  1 , Laura WATKINS  2 , Gowri SIVALINGAM  2 , Maddison BURMAZ  1 , Anna THETFORD  3 , Elizabeth THOMSON  3 , Emma RICHARDSON  4 , Jane VALENTINE  4 , Anna GUBBAY  4 , Gavan HOTANA  4 , Katherine LANGDON  4 , Naeem SAMNAKAY  2 , Andrew BARKER  2 and Japinder KHOSA  2 1) University of Western Australia, School of Medicine, Dentistry and Health Science, Crawley, AUSTRALIA - 2) Princess Margaret Hospital, Department of Urology, Subiaco, AUSTRALIA - 3) Princess Margaret Hospital, Clinical Nurse Specialist, Multidisciplinary Spinal Clinic, Subiaco, AUSTRALIA - 4) Princess Margaret Hospital, Department of Rehabilitation Medicine, Subiaco, AUSTRALIA PURPOSE To compare the patient experience of transdermal (TOP) versus oral oxybutynin in paediatric patients with neuropathic bladder. MATERIAL AND METHODS Patients with neuropathic bladder were identified via the multidisciplinary spinal rehabilitation clinic. Patients had trialled TOP and/or oral oxybutynin for greater than 6 weeks. Aquestionnaire and rating scale was developed to report efficacy, compliance and side effects. Retrospective demographics and outcomes data was collected through phone or face-to-face interview. RESULTS 27 patients (mean age 10) met inclusion criteria, with 18 having tried both TOP and oral prepara- tions and 9 having tried only TOP. Of the patients that had tried both formulations, 12 (66.6 %) preferred TOP. Reasons for preference were ease of use (50 %) and fewer side effects (41.7 %). 6 participants preferred oral medication, reasons cited included patch falling off (50 %) and skin irritation (33.3 %). Patient reported efficacy and compliance data was reported on a scale of 1–5 (optimal). Patient reported control with TOP was 3.85 vs 3.41 for oral (p <0.1). Compliance was reported in terms of ease of use and frequency of missed doses. TOP was missed less frequently (1.89 vs 2.59, p <0.05) and found to be easier to use (4.33 vs 3.70, p <0.1). Of those taking oral medication, 38.9 % reported systemic side effects at least ‘somewhat' bothersome compared to only 14.8 % of those using TOP. 25.9 % of those using TOP reported local side effects that were at least ‘somewhat' bothersome (redness or itch at application site). CONCLUSIONS TOP has better patient compliance and reported efficacy compared to the oral formulation in this population. It is the preferred formulation due to ease of use and minimal side effects. Topical oxybutynin is a good alternative to oral medication in children with neuropathic bladder.